Suppr超能文献

乳腺癌粗针穿刺活检与手术标本的组织学恶性分级、雌激素受体(ER)和人表皮生长因子受体2(HER2)状态的可靠性

Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.

作者信息

Munch-Petersen Helga D, Rasmussen Birgitte B, Balslev Eva

机构信息

Department of Pathology, Herlev Hospital, Herlev, Denmark.

出版信息

APMIS. 2014 Sep;122(9):750-4. doi: 10.1111/apm.12213. Epub 2013 Dec 21.

Abstract

Early determination of malignancy grade and biomarkers in primary breast cancer is important when planning the treatment with neoadjuvant therapy and breast-conserving surgery. The aim of this study was to assess the reliability of malignancy grade on core needle biopsies, and to compare the concordance of ER and HER2 status on core needle biopsies vs surgical specimens. Eighty-nine patients with invasive ductal or lobular carcinoma were included. Malignancy grade was upgraded by one degree in 23.0%. The mitotic count had most impact on the malignancy grade, and may be underestimated on core needle biopsies compared with surgical specimens. ER status was concordant in core needle biopsies and surgical specimens in 98.0%, but should be repeated when doubtfully negative. HER2 status was concordant in 84.0% prior to FISH-HER2. Including FISH-HER2 data, the core needle biopsies showed a final total concordance of 95.4%. In conclusion, ER and HER2 are useful markers in core needle biopsies, providing a reliable base for preoperative decisions in neoadjuvant chemotherapy, and may be omitted on surgical specimens with certain precautions and exceptions. Determination of malignancy grade should be repeated on surgical specimens, and one should be aware of underestimation on core needle biopsies.

摘要

在规划新辅助治疗和保乳手术时,早期确定原发性乳腺癌的恶性程度和生物标志物非常重要。本研究的目的是评估粗针活检中恶性程度分级的可靠性,并比较粗针活检与手术标本中雌激素受体(ER)和人表皮生长因子受体2(HER2)状态的一致性。纳入了89例浸润性导管癌或小叶癌患者。23.0%的患者恶性程度分级上调一级。有丝分裂计数对恶性程度分级影响最大,与手术标本相比,粗针活检可能会低估有丝分裂计数。ER状态在粗针活检和手术标本中的一致性为98.0%,但当结果可疑为阴性时应重复检测。在进行荧光原位杂交检测HER2(FISH-HER2)之前,HER2状态的一致性为84.0%。纳入FISH-HER2数据后,粗针活检的最终总体一致性为95.4%。总之,ER和HER2是粗针活检中的有用标志物,为新辅助化疗的术前决策提供了可靠依据,在采取一定预防措施并存在某些例外情况时,手术标本检测可省略。手术标本应重复进行恶性程度分级测定,且应注意粗针活检可能存在低估情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验